Venue: Tower Hall Funabori 7134-0091 4-1-1 Funabori Edogaw-ku Tokyo

As of 2013/4/3

Register Now!

April 11 Annual General Meeting 9:30-10:30

	09:30-10:30	60	9:30-11:30 Annual General Meeting	MC: Shigeru Nakamura	Head of Secretariat	
			Welcome	Tatsuro Miyagawa	Chairman	
			Nomination and Election of AGM chairman			
			2012 Activity Report	Shigeru Nakamura	Head of Secretariat	
CE Main Hall			2012 Financial Report	Yuichi Watanabe	Treasurer	
5F Main Hall			2012 Internal Audit Report	Hiroshi Kyogoku	Japan Affiliate Auditor	
			2012 Action Plan	Shigeru Nakamura	Head of Secretariat	
			2013 Budget Proposal	Yuichi Watanabe	Treasurer	
			Bylaw Revision	Tsutomu Samura	Past Chairman	
			2013-2014 Election Results of Board & Officers	Katsuhiko Nagao	Executive Director / 2012 Head of Election Committee	

April 11 Annual Conference 10:40-18:00

Venue	Time	Minutes	3	Title	Speaker		Moderator	
5F Main Hall	10:40-10:50	10			MC:Shigeru Nakamura	Japan Affiliate Head of Secretariat, CM Plus Corporation		
			Welcome Remarks 1		2013 Japan Affiliate Chairman	ISPE Japan Affiliate		
	10:50-11:30	40	Keynote Speech 1	Situation of PIC/S accession of Japan and revision of GMP notification	Shingo Sakurai	PMDA	Tetsuhito Takarada	Japan Affiliate Executive Director, Mochida Pharmaceutical Co., LTD.
	11:30-12:10	40	Keynote Speech 2	ASEAN Harmonization on GMP Inspection and Training of Inspector	Sia Chong Hock	Singapore HSA (health Sciences Authority)	Tetsuhito Takarada	Japan Affiliate Executive Director, Mochida Pharmaceutical Co., LTD.
2F Event Hall	12:10-13:10	60	Lunch					
5F Main Hall	13:10-13:50	40	Keynote Speech 3	EU and PIC/S, what is new in GMPs, in APIs and in GDPs	Vasiliki Revithi	PIC/S Executive Bureau Member, Chair of Compliance Group monitoring new applications to PIC/S, ex-Head of the GMDP Inspectorate at the National Organization for Medicines of Greece (EOF)	Tsutomu Samura	Past Chairman Sanofi K.K.
2F Event Hall	13:50-14:00	10	Break					
5F Main Hall	14:00-15:20	80	Panel Discussion	TING Growing Intiliance of PIC/S Internationally	Shingo Sakurai, Sia Chong Hock, Vasiliki Revithi, Tetushito Takarada,	Three Regulators and a Panelist from Industry	Bob Tribe	Former Chair of PIC/S, Asia-Pacific Regulatory Affairs Adviser, ISPE
2F Event Hall	15:20-15:50	30	Coffee Break					
5F Main Hall	15:50-16:40	50	Special Lecture 1	Overcoming Challenges: Growth Strategy of MSD as Global Healthcare Company	Tony Alvarez	MSD KK, Representative Director and President	Yuichi Watanabe	Japan Affiliate Treasurer, MSD KK
	16:40-17:30	50	Special Lecture 2	Our Quest for Growth	Taro Iwamoto	Otsuka Pharmaceutical Co., Ltd. Representative Director and President	Tatsuro Miyagawa	Japan Affiliate 2012 Chairman, CMIC CMO CO., LTD.
2F Event Hall	18:00-20:00	120	Networking Party					

April 12 Workshops 9:00~17:00

Venue	Time	Minutes		Title	Speaker		Moderator	
2F Zuiun	9:00-17:00 Wor	ksho	o 1: Regulatory Commi	ttee (PQLI, SAM&GMP) / API COP				
	New Evolution	of Glo	obal GMP - Challenge a	nd Realization	MC: Tsutomu Kojima	Ono Pharmaceutical Co., Ltd.		
	Part1: Global G	МР а	nd PQS (ICHQ10)					
	9:00-9:40	40	Special Lecture 1	GMPs in EU and ICH Q10 impact	Vasiliki Revithi	PIC/S Executive Bureau Member, Chair of Compliance Group monitoring new applications to PIC/S, ex-Head of the GMDP Inspectorate at the National Organization for Medicines of Greece (EOF)	Tetsuhito Takarada	Japan Affiliate Executive Director, Mochida Pharmaceutical Co., LTD.
AM	9:40-10:20	40	Special Lecture 2	Towards a Robust & International GMP Inspection System	Sia Chong Hock	Singapore HSA (health Sciences Authority)		,
	10.00 10.10	00	Break	Opportunities, Benefits & Challenges				
	10:20-10:40							Japan Affiliate Board of Director, Chair of Regulator
	10:40-11:20		Lecture 1	Example of introduction of PQS to GQP	Tetsuhito Takarada	Mochida Pharmaceutical Co., Ltd.	Yoshio Kitazawa	Committee, National Institute of Health Science
	11:20-12:00		Lecture 2	Approach to Global Quality / GMP System	Shigehiro Higuchi	Takeda Pharmaceutical Co., Ltd.	Takayuki Oowaki	Japan Affiliate Board of Director, PQLI Leader, Fisal Co. Ltd.
2F Zuiun	12:00-13:00 Part 2: New Pa		Lunch n for Development and	Manufacturing of API and Drug Product				
Li Luiuii	13:00-13:50		Special Lecture 3	ICH Q11, Expectations and Status	Kazunori Takagi	PMDA	Ayako Nakajima	Japan Affiliate Board of Director,
	13.00-13.50		•	Development of Virtual API HMCIN based on ICHQ11and Risk	Kazunon Takagi		Ауако макајіта	NISSAN CHEMICAL INDUSTRIES, LTD.
	13:50-14:30	40	Report 1	Based Approach for the Plant Design	Yasutaka Takada	Nissan Chemical Industries, Co., Ltd.	Susum Honda	Japan Affiliate Board of Director,
РМ			Report 2	Risk Based Approach to Planning and Designing the Virtual HMCIN Manufacturing Plant	Masahiro Kawano	lec	Cucum Florida	NIPRO PHARMA CORPORATION
	15:20-15:40		Break					217.0021 1 5 1 1 1 1 1 1
	15:40-16:20	40	Report 3	Control Strategy for Fluid-bed Granulation	Satoru Arai	Toray Industries, Inc.	Menetaka Hattori	PAT COP Leader, Former Japan Affiliate Chairman
	16:20-17:00	40	Report 4	A Simulation and Model-building for the Virtual Drug Development of HM Tablet by Introducing the Concept of Quality Engineering	Tsuyoshi Sago	Mochida Pharmaceutical Co., Ltd.	Masaki Hasegawa	Leader of SAM&GMP Committee, Mie Pref Science & Technology Promo Ctr
2F Heian	9:00-12:30 Wor	ksho	2:BIO COP		MC: Sei Murakami	Chair of BIO COP, Hitachi, Ltd.		Chair of BIO COP, Hitachi, Ltd.
	Trends in Biop	harma	aceutical Manufacturing	g and Single-Use Technologies				
	9:00-10:00	60	Lecture	Trends in Biologics Development and Regulation	Teruhide Yamaguchi	National Institute of Health Sciences		
				Single-Use Technologies in Biopharmaceutical Manufacturing	Atsushi Wakai	Thermo Fisher Scientific K.K.		
					Satoshi Igarashi	SARTORIUS K.K.	Sei Murakami	
AM	10:00-12:00				Mami Okudaira	GE Healthcare Japan Corporation		
Aivi		120	Workshop		Satoshi Tomita Hirotoshi Awatsu	TAITEC CORPORATION Nihon Pall Ltd.		
					Hiroyuki Matsuda	FUJIMORI KOGYO COLTD		
					Takashi Maekawa	MATSUBO Corporation		
					Mika Araki	Merck Ltd. Japan		
	12:00-12:15		Workshop	ASME BPE 2012 Outline	Sei Murakami	Chair of BIO COP, Hitachi, Ltd.		
	12:30-13:30	60	Lunch					
2F Heian			op 4:GAMP COP		MC: Akiko Sugiura	FUJI XEROX INFORMATION SYSTEMS CO., LTD.		
			nt of GAMP 5 Related G	Suidance Summary of GAMP Japan COP Activities and GAMP 5 Related				
	13:30-13:50	20	Lecture 1	Guidances	Takayuki Sugimoto	Chair of GAMP Japan COP, SOAS Inc.		
	13:50-14:40		Lecture 2	Introduction to GAMP® Good Practice Guide: A Risk-Based Approach to GxP Process Control Systems Second Edition	Hirokazu Hasegawa	GAMP COP SIG2 Sub Leader, Mylan Seiyaku Ltd.	Takayuki Sugimoto	Chair of GAMP Japan COP, SOAS Inc.
	14:40-15:10	30	Coffee Break	Interduction to CAMPO Co. I.D. vis. O. i. t.				
PM	15:10-16:00	50	Lecture 3	Introduction to GAMP® Good Practice Guide: Manufacturing Execution Systems -A Strategic and Program Management Approach (Japanese version)	Kazuhiro Matsumura	GAMP COP SIG1 Leader, Nihon Techno Kaihatsu Co.,Ltd		o Chair of GAMP Japan COP, SOAS Inc.
	16:10-17:00			Comparison Examination of Other IT-Related Guidelines with GAMP 5 - IT Outsourcing under GxP Regulations -	Hiroomi Nishimura, Masato Kato	GAMP COP SIG4 Leader, Shimadzu Corporation, GAMP COP SIG4, MSD K.K.	Takayuki Sugimoto	
			Lecture 4 and Panel	Panel Discussion	MC:Hiroomi Nishimura	Shimadzu Corporation		
		50	Discussion		Masato Kato,	MSD K.K.,		
					Naoki Ozawa, Atsushi Aminaka,	Nippon Shinyaku Co., Ltd., CAC EXICARE Corporation,		
					Yoshihiko Suzuki	NEC Corporation		
2F Fukujyu	9:00-12:30 Wor	ksho	3:IP COP		MC: Shuji Hongo	IP-COP lead, Astellas Pharma Inc.		
	Seminar for Ne	wly P	ublished Japanese Edi	tion of "Comprehensive Guide to Clinical Materials: A Handbook				
	9:00-9:05	5		Opening remarks	Shuji Hongo	IP-COP lead, Astellas Pharma Inc.		
	9:05-9:35		Chapter 1 Chapter 2	Introduction	Yu Kushimoto	IP-COP, Fisher Clinical Services Japan K.K.	Hirofumi Suzuki Chiaki Yamauchi	Japan Affiliate Board of Director, Bayer Yakuhin, Ltd.
		30		Acknowledgements				
			Chapter 3	Regulatory/GxP Information				
AM	9:35-10:05	30	Chapter 4	Project Planning and Management and Clinical Trials Design	Shuji Hongo	IP-COP lead, Astellas Pharma Inc.		
	10:05-10:45	40	Chapter 5	Manufacturing	Kaoru Oda Chie Igushi	IP-COP, Novartis Pharma K.K. IP-COP, Pfizer Japan Inc.		IP-COP, Nippon Boehringer Ingelheim Co., Ltd.
	10:45-11:00		Break		- Indiana in the second in the			
	11:00-11:30		Chapter 6	Distribution and Returns	Toshiya Soejima	IP-COP, Bayer Yakuhin, Ltd.		
	11:30-12:00		Lecture 1	IVRS/IWRS	Satoru Kono	IP-COP, e-Trial Co.,Ltd.	Yoshihiko Sato	IP-COP, Mitsubishi Logistics Corporation
	12:00-12:30 12:30-13:30	-	Lecture 2 Lunch	IP Warehousing and Distribution in Clinical Trials	Kazuaki Abe	IP-COP, WORLD COURIER		
	12.00-13.30	00	Luttott					